Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,450 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety in Healthy Adults Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

NCT02871037
View directory record Official record
Conditions
Normal Healthy
Interventions
PF-05221304, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Traveler's Diarrhea (TD) Automated Process

NCT00751777
View directory record Official record
Conditions
Prevention of Travelers' Diarrhea
Interventions
heat-labile enterotoxin of E. coli (LT), Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Vallejo, California • South Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

NCT00630331
View directory record Official record
Conditions
Influenza
Interventions
Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine, Placebo
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
11,404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
17
States / cities
Denver, Colorado • Pembroke Pines, Florida • South Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

NCT03950856
View directory record Official record
Conditions
Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
V114, Prevnar 13™
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
2,340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
30
States / cities
Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01436422
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 30, 2026, 1:30 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pancoronavirus Vaccine Study in Healthy Adults

NCT06950177
View directory record Official record
Conditions
COVID-19 Respiratory Infection, SARS CoV 2 Infection, COVID-19 Vaccine
Interventions
CoV-RBD-scNP-001 and 3M-052-AF
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults

NCT00054860
View directory record Official record
Conditions
HIV Infections
Interventions
EP HIV-1090
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

NCT00001020
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1IIIB, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine

NCT00677820
View directory record Official record
Conditions
Influenza
Interventions
Trivalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2010 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants

NCT05756920
View directory record Official record
Conditions
Healthy
Interventions
ABL301, Placebo
Drug
Lead sponsor
ABL Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults

NCT05901636
View directory record Official record
Conditions
Influenza Prevention
Interventions
INFLUENZA G1 mHA, Placebo, Al(OH)3
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 45 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami Lakes, Florida • Lenexa, Kansas • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 30, 2026, 1:30 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

NCT06980428
View directory record Official record
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers

NCT04243863
View directory record Official record
Conditions
Healthy Volunteers
Interventions
VNRX-7145, Placebo
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 45 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

NCT01260727
View directory record Official record
Conditions
HIV Infections
Interventions
PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

NCT01593046
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 Oral, GSK1265744 LAP 800mg intramuscular injection, GSK1265744 LAP 200mg subcutaneous injection, GSK1265744 LAP 200mg intramuscular injection, GSK1265744 LAP 400mg intramuscular injection, TMC278 LA 1200mg intramuscular injection, TMC278 LA 600mg intramuscular injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Daytona Beach, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

NCT04503603
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lanadelumab, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

NCT06436703
View directory record Official record
Conditions
Influenza, Human
Interventions
Influenza ModRNA Vaccine, Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
32
States / cities
Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 30, 2026, 1:30 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Ashwagandha Pharmacokinetics Study in Older Adults

NCT06171724
View directory record Official record
Conditions
Healthy, Aging
Interventions
Shoden
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
65 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers

NCT01952548
View directory record Official record
Conditions
Safety and Tolerability
Interventions
K-312, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Timeline
Started 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

NCT00882726
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Miramar, Florida • San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
View directory record Official record
Conditions
Bacterial Infections
Interventions
TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults

NCT02674347
View directory record Official record
Conditions
Healthy Subjects
Interventions
3 g or 6 g Zidebactam, Placebo
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants

NCT03325075
View directory record Official record
Conditions
Chikungunya Virus
Interventions
VAL-181388, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 30, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

NCT04816669
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
629 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
21
States / cities
Anaheim, California • Walnut Creek, California • Hialeah, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 30, 2026, 1:30 PM EDT